Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04768036
Other study ID # 20-0752
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 21, 2020
Est. completion date January 21, 2022

Study information

Verified date July 2022
Source Northwell Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be a multicenter clustered randomized trial of patients in hospitals in which a universal "SMART on FHIR" platform-based EHR-embedded IMPROVE DD VTE clinical prediction rules (CPRs) with electronic order entry has been incorporated into required admission and discharge EHR workflow versus hospitals following UMC for VTE risk assessment of medically ill patients. The patient population will consist of hospitalized, medically ill (non-surgical, non-obstetrical) individuals aged > 60 years.


Description:

Investigators, plan to do a study using a pragmatic, randomized design as part of a Quality Improvement (QI) project as a substudy within the existing NIH R18 proposal of creating a universal "SMART on FHIR" platform of the IMPROVE VTE CPR for key Northwell Health hospitals. Investigators, aim is to assess whether an EHR-embedded CPR for VTE prevention - the IMPROVE VTE CPR - ultimately tied to electronic order entry will increase the proportion of hospitalized medical patients at risk of VTE who receive appropriate thromboprophylaxis, both at hospital admission AND at hospital discharge, compared to UMC. Investigators, secondary aims are to assess whether key adverse outcomes such as symptomatic VTE and hospital readmission for VTE are reduced and whether health -resource utilization metrics are improved.


Recruitment information / eligibility

Status Completed
Enrollment 10699
Est. completion date January 21, 2022
Est. primary completion date January 21, 2022
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: • Patients with an acute medical illness and ONE of the following risk factors: - Age > 60 years - Presence of known thrombophilia - Intensive care unit (ICU)/coronary care unit (CCU) stay - Lower extremity paralysis - Cancer - Immobilization - Previous VTE history - D-dimer (>2X ULN) Exclusion Criteria: • Patients with the following factors: - Therapeutic anticoagulation - History of recent bleeding. - Active gastroduodenal ulcer - Thrombocytopenia (admission platelet count< 75x 109 cells/L ) - Coagulopathy (baseline INR > 1.5) - Severe renal insufficiency (baseline)CrCl < 30ml/min) - Dual antiplatelet therapy - Bronchiectasis/pulmonary cavitation - Active cancer, and recent major surgery within 30 days of their index hospitalization bleeding.

Study Design


Intervention

Other:
IMPROVE DD VTE Tool
Universal "SMART on FHIR" platform-based EHR-embedded IMPROVE VTE CPR with electronic order entry incorporated into required admission and discharge EHR workflow.

Locations

Country Name City State
United States North Shore University Hospital Manhasset New York
United States The Institute for Health Innovations and Outcomes Research Manhasset New York
United States Long Island Jewish Medical Center New Hyde Park New York
United States Lenox Hill Hospital New York New York
United States Staten Island University Hospital Staten Island New York

Sponsors (1)

Lead Sponsor Collaborator
Northwell Health

Country where clinical trial is conducted

United States, 

References & Publications (2)

Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB, Monreal M, Merli GJ, Pavanello R, Turpie AGG, Nakamura M, Piovella F, Kakkar AK, Spencer FA; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. doi: 10.1378/chest.10-1944. Epub 2011 Mar 24. — View Citation

Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 Aug 30;117(9):1662-1670. doi: 10.1160/TH17-03-0168. Epub 2017 Jun 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the impact of implementing a multicenter QI program using a universal for type and duration of thromboprophylactic agent Specifically, our pilot study will determine if this QI intervention will result in a greater increase in the proportion of at-VTE or high-VTE risk medical patients that are treated with an appropriate thromboprophylactic agent, both during hospitalization and in the post-hospital discharge period using a 5-point score where 0-1 constitutes low VTE risk, 2-3 constitutes moderate VTE risk, and 4 constitutes high VTE risk. 90 days
Secondary Rates of patient VTE as assessed by the diagnostic and imaging codes for VTE Change in patient rates of VTE - lower extremity deep vein thrombosis (DVT) or PE using objective testing at up to 90 days and VTE-related death by autopsy or objective criteria (ICD codes and CPT diagnostic codes as per Appendix 2). 90 days
Secondary Number of participants with VTE-related readmissions The combined total number of VTE-related readmissions of patients at up to 90 days. 90 days
Secondary Number of participants with all cause readmissions The combined total of the number of patients with all cause hospital readmissions. 90 days
Secondary Change in diagnosis-related group Change in diagnosis-related group of patients from baseline up to 90 days. 90 days
Secondary Change in type of insurance Change in type of insurance for patients from baseline up to 90 days. 90 days
Secondary Change in drug cost Change in drug cost for patients from baseline up to 90 days. 90 days
Secondary Change in prescriber patterns of LMWH (low molecular weight heparin) Change in prescriber patterns for patient use of LMWH, enoxaparin, compared to standard of 40mg SQ QD. 90 days
Secondary Change in prescriber patterns of UFH (unfractionated heparin) Change in prescriber patterns of patient use of UFH, as compared to standard of 5000U SQ BID or TID. 90 days
Secondary Change in prescriber patterns of fondaparinux Change in prescriber patterns of patient use of fondaparinux, as compared to standard of 2.5mg SQ QD. 90 days
Secondary Change in prescriber patterns of rivaroxaban Change in prescriber patterns of patient use of direct oral anticoagulant, rivaroxaban, as compared to a standard of 10mg PO QD. 90 days
Secondary Arterial thromboembolism (ATE) including stroke, transient ischemic attack (TIA), myocardial infarction (MI) 90 days
Secondary Total thromboembolism (VTE and ATE) Including stroke, transient ischemic attack (TIA), myocardial infarction (MI) systemic embolism, acute limb ischemia, lower extremity deep vein thrombosis (DVT). 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05347550 - Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients N/A
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Completed NCT02379806 - The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study Phase 3
Recruiting NCT03691753 - Safety and Efficacy Study of Fitaya Vena Cava Filter N/A
Completed NCT02197416 - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Phase 3
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT01895777 - Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Phase 3
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Completed NCT04736420 - Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Completed NCT04736719 - Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Completed NCT04735523 - Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Completed NCT02912234 - Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants Phase 1
Completed NCT02746185 - Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban Phase 3
Completed NCT02829957 - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Phase 2/Phase 3
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02661568 - Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES) N/A
Completed NCT02223260 - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Phase 2
Completed NCT01431456 - Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery Phase 3
Completed NCT01972243 - Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model